XtalPi, Eli Lilly Announce AI Robotics Collaboration
Partnership to focus on drug discovery platform.
XtalPi, a pharmaceutical technology company, has announced an AI drug discovery collaboration with Eli Lilly, receiving up to $250 million in milestone payments. Per the agreement, XtalPi will utilize its robotics platform in order to deliver drug candidates for an undisclosed target.
"With a closed loop of AI and quantum physics algorithms working in sync with the data factory of large-scale robotics experiments, XtalPi is uniquely equipped to tackle challenging novel targets,” said Dr. Jian Ma, CEO of XtalPi. “We are honored that Lilly has chosen XtalPi’s AI + robotics drug R&D platform as a partner in achieving more fruitful pharmaceutical innovation and bringing much-needed treatments to patients worldwide."
Reference: XtalPi Announces Collaboration with Lilly, Using AI + Robotics to Uncover First-in-class Therapeutics. May 30, 2023/Xpalti
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
